FIELD: pharmaceuticals.
SUBSTANCE: invention concerns a tablet containing candesartan or candesartan cilexetil and amlodipine or its pharmaceutically acceptable salt as active ingredients. In addition to said combination of active substances, the declared tablet also contains macrogol-15-hydroxystearate as a solubilising agent.
EFFECT: use of the disclosed solubilizer in the tablet provides higher stability of the active substances for a long storage period, as well as improved solubility of the tablet in the gastrointestinal tract or digestive tract of the body, which enables to maintain the level of the drug in the blood at a constant level.
8 cl, 16 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPLEX FORMULATION COMPRISING ANGIOTENSIN II RECEPTOR BLOCKER AND HMG-CoA REDUCTASE INHIBITOR | 2014 |
|
RU2662565C2 |
| SOLID MEDICATION OF OLMESARTAN MEDOXOMIL AND AMLODIPINE | 2007 |
|
RU2423975C2 |
| PHARMACEUTICAL COMBINATION FORMULATION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2014 |
|
RU2660586C1 |
| PHARMACEUTICAL COMPLEX COMPOSITION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2016 |
|
RU2724338C2 |
| COMPLEX PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, LOSARTAN AND CHLORTHALIDONE | 2016 |
|
RU2713883C2 |
| COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
| MULTI-LAYERED TABLET, CONTAINING EFFERVESCENT LAYER | 2010 |
|
RU2547562C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE AND LOSARTAN | 2007 |
|
RU2401107C2 |
| PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
| PHARMACEUTICAL PREPARATION | 2019 |
|
RU2756452C1 |
